Arterial	arterial	O	O	O	O
thromboembolism	thromboembolism	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
systemic	systemic	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
:	:	O	O	O	O
a	a	O	O	O	O
complication	complication	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Arterial	arterial	O	O	O	O
thromboembolism	thromboembolism	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
recognized	recognized	O	O	O	O
complication	complication	O	O	O	O
of	of	O	O	O	O
systemic	systemic	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Characteristic	characteristic	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
entity	entity	O	O	O	O
is	is	O	O	O	O
arterial	arterial	O	O	OTHERS	I
occlusion	occlusion	O	O	OTHERS	I
by	by	O	O	O	O
platelet-fibrin	platelet-fibrin	O	O	O	O
thrombi	thrombi	O	DISEASE	OTHERS	I
with	with	O	O	O	O
distal	distal	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
occurring	occurring	O	O	O	O
four	four	O	O	O	O
to	to	O	O	O	O
twenty	twenty	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
preceded	preceded	O	O	O	O
by	by	O	O	O	O
profound	profound	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
platelet	platelet	O	O	O	O
counts	counts	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
range	range	O	O	O	O
of	of	O	O	O	O
30,000	30,000	O	O	O	O
to	to	O	O	O	O
40,000	40,000	O	O	O	O
per	per	O	O	O	O
cubic	cubic	O	O	O	O
millimeter	millimeter	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
clinically	clinically	O	O	O	O
apparent	apparent	O	O	O	O
occlusion	occlusion	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
preceded	preceded	O	O	O	O
by	by	O	O	O	O
gastrointestinal	gastrointestinal	O	O	O	O
and	and	O	O	O	O
musculoskeletal	musculoskeletal	O	O	O	O
symptoms	symptoms	O	O	O	O
that	that	O	O	O	O
appear	appear	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
ischemic	ischemic	O	O	OTHERS	I
in	in	O	O	O	O
origin	origin	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
might	might	O	O	O	O
serve	serve	O	O	O	O
to	to	O	O	O	O
warn	warn	O	O	O	O
the	the	O	O	O	O
clinician	clinician	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
complications	complications	O	O	O	O
.	.	O	O	O	O

Previous	previous	O	O	O	O
reports	reports	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
phenomena	phenomena	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
recent	recent	O	O	O	O
studies	studies	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
reviewed	reviewed	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
common	common	O	O	O	O
factor	factor	O	O	O	O
relating	relating	O	O	O	O
thromboembolism	thromboembolism	O	O	OTHERS	I
and	and	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
is	is	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
platelet	platelet	O	DISEASE	OTHERS	I
aggregation	aggregation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Appropriate	appropriate	O	O	O	O
treatment	treatment	O	O	O	O
consists	consists	O	O	O	O
of	of	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
with	with	O	O	O	O
sodium	sodium	CHEMICALS	O	OTHERS	I
warfarin	warfarin	CHEMICALS	O	OTHERS	I
if	if	O	O	O	O
necessary	necessary	O	O	O	O
.	.	O	O	O	O

Vascular	vascular	O	O	O	O
procedures	procedures	O	O	O	O
are	are	O	O	O	O
performed	performed	O	O	O	O
as	as	O	O	O	O
indicated	indicated	O	O	O	O
.	.	O	O	O	O

